Access and Health Security

Access to Our Products

Our products provide substantial and meaningful value to patients, healthcare providers, health insurance payers and healthcare systems around the world.

We are proud of these contributions and seek to ensure that patients and communities have access to a reliable supply of biopharmaceuticals and vaccines.

We work with governments, health insurance payers and other stakeholders to support timely and appropriate market entry and access, in order to enable appropriate patients to benefit from our therapies as quickly as possible. We value an ongoing dialogue with policymakers, advocacy groups and other stakeholders to understand and respond to their needs and expectations.

We articulate and communicate comprehensive evidence on the value of our innovations to inform access and reimbursement decisions, and we provide patient assistance programs and support advocacy efforts that improve access to care and affordability.

We are also committed to pricing practices that reflect the value our products bring to patients and society. To that end, we evaluate real-world and clinical trial data that demonstrate the clinical benefits our therapies deliver, as well as the cost they provide to overall healthcare. We also consider patient needs and preferences and how our therapies improve patients’ quality of life and productivity.

Bleeding Disorders

For more than 10 years, CSL Behring has supported the World Federation of Hemophilia (WFH) to improve the diagnosis and treatment of bleeding disorders around the world.

In addition to its financial support for the organisation’s work, CSL Behring is a program sponsor and donor to the WFH’s Global Alliance for Progress (GAP) Program, a worldwide initiative seeking to save and improve the quality of life of people with bleeding disorders.

In May 2022, CSL Behring announced a ground-breaking new partnership with the World Federation of Hemophilia (WFH). Commencing in 2023, CSL Behring will donate 500 million international units (IUs) of coagulation factor therapy to the WFH, including product specifically manufactured for the purposes of being donated, creating consistent and reliable access to treatment for people living with bleeding disorders in more than 60 developing countries.

By manufacturing product specifically for the purposes of donation, the coagulation factor therapy will have a standard shelf life of three years, thus enabling greater access to these life-saving therapies for people around the world. The donated product will be delivered twice a year for five years.

CSL Behring also provides financial support for logistics costs and training programs designed to address unmet needs for people living with haemophilia in developing countries who are undiagnosed, untreated, or undertreated.

For more details on CSL’s patient and product impact as a result of the partnership see our detailed case study - Improving access in developing countries for patients with bleeding disorders - in section 9 of our Annual Report.

Influenza

CSL Seqirus supports the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework which aims to improve the sharing of influenza viruses with pandemic potential and the equitable access to products necessary to respond to an influenza pandemic including vaccines, antivirals and diagnostics. CSL Seqirus makes an annual financial contribution and has also committed 10% of influenza vaccine output in real time to the WHO for deployment to developing countries in the event of a pandemic emergency.

To further enhance our ability to protect public health, CSL Seqirus entered into a five-year partnership with Pandemic Institute in Liverpool, UK, in 2023, which will deliver on a number of joint projects, such as modelling the spread and impact of avian influenza ahead of a potential pandemic.

Primary Immunodeficiency

The Jeffrey Modell Foundation is devoted to early and precise diagnosis, meaningful treatments and, ultimately, cures for those with primary immunodeficiency (PI). CSL Behring has been a partner to this organization and its important work of creating PI diagnostic and research centers since its inception over 30 years ago.

In March 2017, the foundation announced its plans to open its first PI network and center in Africa, with CSL Behring a proud sponsor. The North African Network will join over 200 similar sites in the Jeffrey Modell Centers Network around the world. These centers offer advanced diagnostic evaluations to patients with suspected primary immune deficiencies and our support helps CSL to deliver on our promise to PI patients. In Africa, it’s estimated that the diagnosis rate of PI, a life threatening condition, is only about 0.3 percent.

Antivenoms

In April 2018, a new multi-stakeholder partnership was launched in Papua New Guinea (PNG), the “PNG Snakebite Project”, to help save lives from snakebite. PNG has some of the highest rates of snakebite mortality in the world, caused mainly by taipan and death adder envenomation. The same snake species are found in Australia, where Seqirus antivenom has been in use for decades.

The partnership, involving the PNG National Department of Health, the Australian High Commission, Seqirus and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea, is intended to significantly improve access to antivenoms by combining a large product donation, healthcare worker training, plus a purpose-built cold-chain distribution and product management system.

Under the partnership, Seqirus will provide an annual donation of 600 vials of snake and marine creature antivenoms to PNG valued at more than A$1 million annually.

During the COVID-19 pandemic, the program has found innovative ways to open up access to more remote parts of the country through collaborations with St John Ambulance on the roads of Central Province, Manolos Aviation to leverage the airspace above Lae and beyond, and the Youth with a Mission (YWAM) Medical Ship that serves communities along the southern coast of PNG.

Health Security

A measure of the trust we have built is our position as a global leader in influenza pandemic preparedness and response. Thirty governments around the world rely on CSL Seqirus for pandemic influenza preparedness, including the US, the UK and Australia. CSL Seqirus also provides pandemic response commitments to the World Health Organization.

Our government partners reserve pandemic vaccine doses from our facilities to protect their populations in the event of an influenza pandemic. CSL Seqirus also supplies pre-pandemic vaccine stockpiles that could be deployed to first responders upon a declaration of an influenza pandemic.

CSL Seqirus has three state-of-the-art manufacturing facilities on three different continents, together with a global fill and finish network located close to our end markets.

In February 2022, CSL Seqirus renewed a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).